The findings indicate a significant upregulation of ATP6V1C1 in most tumors (n=25), notably in breast invasive carcinoma (BRCA), pancreatic adenocarcinoma (PAAD), and liver hepatocellular carcinoma (LIHC) (Figure 7A). Here, ATP6V1C1 is linked to invasive breast carcinoma.